

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Primary results of the Phase III GALLIUM trial evaluating obinutuzumab or rituximab in combination with chemotherapy for newly diagnosed FL demonstrated statistically significant improvement in \_\_\_\_\_ for patients who have received obinutuzumab.**

  - Three-year PFS
  - Three-year overall survival
  - Three-year time to next treatment
  - All of the above
  - Both a and b
  - Both a and c**
- 2. Which of the following statements is true regarding the FLT3-ITD and FLT3-TKD mutations in AML?**

  - FLT3-ITD mutations are more common
  - Both mutations cannot occur in the same patient
  - The combined frequency is approximately 30%
  - Both a and c**
  - All of the above
- 3. Analysis of the IFM/DFCI 2009 trial evaluating immediate or delayed ASCT after RVd induction therapy indicated both PFS and overall response rate benefits for patients who received \_\_\_\_\_.**

  - RVd
  - RVd and ASCT**
  - Neither a nor b — PFS and response rate were equivalent in the 2 study arms
- 4. An analysis of the predictive value of MRD in a subset of patients on the IFM/DFCI 2009 trial demonstrated that MRD negativity from testing by \_\_\_\_\_ was highly predictive of PFS.**

  - Flow cytometry
  - Next-generation sequencing**
  - Both a and b
- 5. Sensitivity to venetoclax for MM has primarily been observed in patients with t(11;14) disease.**

  - True**
  - False
- 6. The Phase III CALGB-10603 (RATIFY) trial evaluating midostaurin in combination with daunorubicin/cytarabine induction therapy and cytarabine consolidation and as maintenance therapy for patients with newly diagnosed AML with FLT3 mutations demonstrated a statistically significant improvement in \_\_\_\_\_ on the midostaurin arm.**

  - Median overall survival**
  - Rate of Grade  $\geq 3$  hematologic adverse events
  - Both a and b
  - Neither a nor b
- 7. CAR-T therapy is currently FDA approved for the treatment of \_\_\_\_\_.**

  - Acute leukemias
  - DLBCL
  - MM
  - None of the above**
- 8. The Phase I/II ACE-CL-001 trial evaluating acalabrutinib for relapsed CLL demonstrated \_\_\_\_\_.**

  - A high response rate
  - A high incidence of bleeding
  - A favorable safety profile
  - Both a and b
  - Both a and c**
- 9. A publication by Ali and colleagues in *Blood* demonstrated for the first time CAR T cells successfully targeting an antigen other than CD19. In this study, which of the following CAR T cells showed activity against MM that was resistant to standard therapies?**

  - Anti-BCMA CAR T cells**
  - Anti-CD38 CAR T cells
  - Both a and b
- 10. Which of the following is the mechanism of action of gilteritinib (ASP2215)?**

  - Anti-CD20 monoclonal antibody
  - CAR-T therapy
  - FLT3 inhibitor**
  - Immunomodulatory drug